Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring

Pembrolizumab, a humanized monoclonal IgG4 antibody directed against programmed death-1, is an immune checkpoint inhibitor that has been introduced for the treatment of non-small-cell lung cancer. However, immune checkpoint inhibitors may cause severe immune-related adverse events. We herein present...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsume, Yumi, Isawa, Tsuyoshi, Toi, Yukihiro, Fukuda, Ryo, Kondo, Yasuteru, Sugawara, Shunichi, Ootomo, Tatsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262691/
https://www.ncbi.nlm.nih.gov/pubmed/29877257
http://dx.doi.org/10.2169/internalmedicine.0255-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262691/
https://www.ncbi.nlm.nih.gov/pubmed/29877257
http://dx.doi.org/10.2169/internalmedicine.0255-17

Ejemplares similares